title: Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.
authors.affiliation: Department of Virology, Schering-Plough Research Institute, Kenilworth, NJ 07033, USA. xiao.tong@spcorp.com
authors.forename: X
authors.initials: X
authors.lastname: Tong
authors.forename: A
authors.initials: A
authors.lastname: Arasappan
authors.forename: F
authors.initials: F
authors.lastname: Bennett
authors.forename: R
authors.initials: R
authors.lastname: Chase
authors.forename: B
authors.initials: B
authors.lastname: Feld
authors.forename: Z
authors.initials: Z
authors.lastname: Guo
authors.forename: A
authors.initials: A
authors.lastname: Hart
authors.forename: V
authors.initials: V
authors.lastname: Madison
authors.forename: B
authors.initials: B
authors.lastname: Malcolm
authors.forename: J
authors.initials: J
authors.lastname: Pichardo
authors.forename: A
authors.initials: A
authors.lastname: Prongay
authors.forename: R
authors.initials: R
authors.lastname: Ralston
authors.forename: A
authors.initials: A
authors.lastname: Skelton
authors.forename: E
authors.initials: E
authors.lastname: Xia
authors.forename: R
authors.initials: R
authors.lastname: Zhang
authors.forename: F G
authors.initials: FG
authors.lastname: Njoroge
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D003521:Cyclopropanes; D004151:Dipeptides / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D055808:Drug Discovery; D004353:Drug Evaluation, Preclinical; D024882:Drug Resistance, Viral / Q000235:genetics; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000201:enzymology* / Q000235:genetics; D006801:Humans; D066298:In Vitro Techniques; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D007700:Kinetics; D007930:Leucine / Q000031:analogs & derivatives; D009154:Mutation; D011392:Proline / Q000031:analogs & derivatives / Q000494:pharmacology; D011480:Protease Inhibitors / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D011994:Recombinant Proteins; D012093:Replicon / Q000187:drug effects; D013450:Sulfones / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*; D014508:Urea; D017361:Viral Nonstructural Proteins / Q000037:antagonists & inhibitors*; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases
chemical_list: D000998:Antiviral Agents; D003521:Cyclopropanes; D004151:Dipeptides; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007930:Leucine; D011392:Proline; D011480:Protease Inhibitors; D011994:Recombinant Proteins; D013450:Sulfones; D014508:Urea; D017361:Viral Nonstructural Proteins; C084422:NS3 protein, hepatitis C virus; D012697:Serine Endopeptidases; D043583:Nucleoside-Triphosphatase; D053487:DEAD-box RNA Helicases; D000085242:Viral Proteases; C552043:narlaprevir; C512204:N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide